Maxim Group Upgrades Palisade Bio Inc. (PALI) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts PALI Hot Sheet
Price: $1.23 --0%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Join SI Premium – FREE
Maxim Group analyst Naz Rahman upgraded Palisade Bio Inc. (NASDAQ: PALI) from Hold to Buy with a price target of $1.50.
For an analyst ratings summary and ratings history on Palisade Bio Inc. click here. For more ratings news on Palisade Bio Inc. click here.
Shares of Palisade Bio Inc. closed at $0.52 yesterday.
You May Also Be Interested In
- DA Davidson Upgrades Broadcom Limited (AVGO) to Buy, 'Looks Like AI Cycle Isn't Over Quite Yet'
- JPMorgan Upgrades KEI Industries Ltd (KEII:IN) to Overweight
- Oppenheimer Reiterates Outperform Rating on Palisade Bio Inc. (PALI)
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
